Kymab is a clinical-stage global biopharmaceutical company focused on the discovery and development of fully human monoclonal antibody drugs using its proprietary antibody platform which contains a full diversity of human antibodies, making it the most comprehensive antibody development platform available.

Biotechnology

Kymab

Kymab's headquarters in Babraham, United Kingdom

Simon Sturge

Allan Bradley

David Melvin

Anne Hyland

Nigel Clark

Martin Nicklasson

Tan Li

Simone Song

Douglas T Fearon

Stephen D. Gillies

Neil H Segal

Kenneth Smith

Alexander Drakesmith

Erwin Boos

Timothy Wells

Dorine Swinkels

Christian Itin

Catherine Moukheibir

Jean-Michel Cosséry

George Demetri

Mark Smyth

Timothy J Rink

David Chiswell

Iain MacDougall

Sergio Quezada

Günter Weiss

The Research and Development Team at Kymab is dedicated to the discovery and advancement of fully human monoclonal antibody drugs. Leveraging the company’s proprietary antibody platform, they conduct cutting-edge research, preclinical studies, and translational biology efforts to develop novel therapies for infectious diseases and other medical conditions. This team collaborates to ensure Kymab’s therapies are innovative and effective, contributing to the company’s mission of improving global health outcomes.

Research and Development Team

The Advisory Team at Kymab provides strategic counsel and expert guidance to steer the company's efforts in the discovery and development of fully human monoclonal antibody drugs. Leveraging their extensive scientific and industry knowledge, the team supports decision-making processes, optimizes research and development strategies, and ensures alignment with the company's long-term objectives.

Advisory Team

The Leadership Team at Kymab plays a pivotal role in guiding the company’s strategic direction, overseeing clinical development, and ensuring the effective management of resources. Comprising key executives such as the CEO, CFO, and Chief Scientific Officer, the team collaborates to drive innovation in antibody therapies, navigate regulatory frameworks, and foster business growth through partnerships and intellectual property management. Their collective expertise ensures Kymab remains at the forefront of biopharmaceutical advancements.

Leadership Team

The Non-Executive Governance Team at Kymab is responsible for providing independent oversight, strategic guidance, and governance to ensure the company's objectives align with stakeholder interests. Comprising the Non-executive Chair and multiple Non-executive Directors, the team leverages their external perspectives and diverse expertise to inform decision-making, enhance corporate governance practices, and contribute to the long-term success of the company.

Non-Executive Governance Team

The Operations Team at Kymab ensures the seamless execution and coordination of daily activities, manages critical project timelines, and supports strategic initiatives. This team, comprising a Project Manager, Senior Director of Operations, and Office & Operations Administrator, optimizes workflows, facilitates effective communication, and maintains operational efficiency to support the company's innovative biopharmaceutical developments.

Operations Team

The Support and Administrative team at Kymab handles essential financial tasks, provides personalized assistance to top executives, and ensures smooth operations within the Research and Development department. This team facilitates efficient communication, scheduling, and administrative support to streamline the discovery and development of innovative monoclonal antibody drugs.

Support and Administrative

Kymab

Org chart

Board & advisors

Teams

Research and Development Team

Advisory Team

Leadership Team

Non-Executive Governance Team

Operations Team

Support and Administrative

Offices

Kymab

Org chart

Board & advisors

Teams

Research and Development Team

Advisory Team

Leadership Team

Non-Executive Governance Team

Operations Team

Support and Administrative

Offices

Related companies